What Researchers Are Learning About GLP-1 Medications and Behavioral Cravings

GLP-1 medications such as semaglutide and tirzepatide have become widely recognized for their role in appetite regulation and weight management. While these medications were originally developed to support glucose regulation, researchers continue to uncover new areas of interest related to how they may affect the brain and behavior.

One emerging area of research involves the potential relationship between GLP-1 signaling and behavioral cravings. Scientists are studying whether these medications may influence reward pathways that extend beyond appetite alone.

This article is intended for educational purposes only and should not be considered medical advice, diagnosis or treatment.

What Are GLP-1 Medications?

GLP-1 stands for glucagon-like peptide-1, a naturally occurring hormone involved in several physiological processes including:

• Appetite regulation
• Satiety signaling
• Gastric emptying
• Glucose metabolism

GLP-1 medications are designed to mimic or enhance the effects of this hormone. Healthcare providers may prescribe GLP-1 therapies for certain patients based on their medical history and treatment goals.

Beyond Appetite Regulation

Many individuals taking GLP-1 medications report changes in their relationship with food. Some describe feeling satisfied with smaller portions, experiencing fewer food-related thoughts or having reduced interest in certain foods.

These observations have led researchers to investigate whether GLP-1 signaling may affect broader reward pathways within the brain.

The brain's reward system helps regulate motivation, pleasure and reinforcement behaviors. Researchers believe some of the same pathways involved in food cravings may also play a role in other reward-seeking behaviors.

The Brain-Gut Connection

The digestive system and brain communicate through a complex network often referred to as the gut-brain axis.

GLP-1 receptors are found not only in the digestive system but also in areas of the brain involved in:

• Appetite regulation
• Decision-making
• Motivation
• Reward processing

Because of this connection, researchers are exploring whether GLP-1 signaling may influence behaviors beyond eating patterns.

What Current Research Suggests

Recent studies and observational reports have generated interest in how GLP-1 medications may affect behavioral cravings.

Researchers have observed that some individuals taking GLP-1 medications report changes in behaviors related to:

• Food cravings
• Alcohol consumption
• Impulse-driven behaviors
• Reward-seeking habits

Scientists have become interested in GLP-1 medications because GLP-1 receptors are found in areas of the brain involved in reward processing, motivation and reinforcement behaviors. Ongoing research is exploring how these pathways may influence cravings and reward-seeking behaviors.

A 2025 study published in JAMA Psychiatry found that semaglutide was associated with reductions in alcohol craving and certain drinking-related outcomes among adults with alcohol use disorder. Researchers noted that larger studies are needed to better understand the findings.

Scientists are continuing to investigate these observations to better understand the relationship between GLP-1 signaling and the brain's reward system.

At this time, researchers are still working to determine the extent of these effects and whether they may have future clinical applications.

Why Researchers Are Interested

The possibility that GLP-1 signaling may influence reward pathways has generated significant scientific interest. 

Understanding these mechanisms could potentially expand knowledge about:

• Appetite regulation
• Behavioral habits
• Reward processing
• Brain-gut communication

Researchers continue to conduct clinical studies to better understand these complex interactions.

Important Limitations

While emerging research is promising, it is important to understand the current limitations.

GLP-1 medications are not FDA-approved for the treatment of:

• Alcohol use disorder
• Substance use disorders
• Behavioral addictions

Additional research is needed before conclusions can be made regarding any potential role of GLP-1 medications outside of their currently approved uses.

Individuals should only use prescription medications under the guidance of a licensed healthcare provider.

Final Thoughts

The relationship between GLP-1 medications and behavioral cravings is an exciting area of ongoing research. Scientists continue to explore how these medications may interact with reward pathways and brain-gut signaling systems.

While many questions remain unanswered, the growing body of research highlights the complex role GLP-1 signaling may play in appetite regulation and human behavior.

As research evolves, healthcare providers and patients alike may gain a deeper understanding of how these therapies affect overall health and wellness.

Learn More About GLP-1 Options

TeleWellnessMD® connects patients with licensed healthcare providers who can discuss available GLP-1 therapies and determine whether treatment may be appropriate based on individual health needs and goals.

Explore Wellness Support Options

This content is for educational and informational purposes only and should not be interpreted as medical advice. TeleWellnessMD® is a technology platform that connects patients with licensed healthcare providers. TeleWellnessMD® does not practice medicine, provide medical advice, or dispense medications. All therapies require evaluation and approval by a licensed healthcare provider. Results may vary.

References:
Hendershot CS, Stangl BL, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder. JAMA Psychiatry. 2025.
Klausen MK, Thomsen M, et al. The Role of Glucagon-Like Peptide-1 (GLP-1) in Addictive Disorders. 2022.